Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors

Steroids

Volumn 72, Issue 14, 2007, Pages 939-948

  Moreira, Vânia M A ^a   Vasaitis, Tadas S ^b   Njar, Vincent C O ^b   Salvador, Jorge A R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; CYP17; Indazole; PC cell lines; Prostate cancer

Indexed keywords

16 FORMYL 17 (1H INDAZOL 1 YL)ANDROSTA 5,16 DIEN 3BETA YLACETATE; 16 FORMYL 17 (2H INDAZOL 2 YL)ANDROSTA 5,16 DIEN 3BETA YLACETATE; 17 (1H INDAZOL 1 YL)ANDROSTA 4,16 DIEN 3 ONE; 17 (1H INDAZOL 1 YL)ANDROSTA 5,16 DIEN 3BETA OL; 17 (1H INDAZOL 1 YL)ANDROSTA 5,16 DIEN 3BETA YLACETATE; 17 (2H INDAZOL 2 YL)ANDROSTA 4,16 DIEN 3 ONE; 17 (2H INDAZOL 2 YL)ANDROSTA 5,16 DIEN 3BETA OL; 17 (2H INDAZOL 2 YL)ANDROSTA 5,16 DIEN 3BETA YLACETATE; 17 CHLORO 16 FORMYLANDROSTA 5,16 DIEN 3BETA YLACETATE; 17 CHLOROANDROSTA 5,16 DIEN 3BETA YLACETATE; ANDROGEN RECEPTOR; ANDROSTANE DERIVATIVE; BICALUTAMIDE; CYTOCHROME P450 17; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; PRASTERONE ACETATE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN BINDING;

BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 35349005731     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.08.004     Document Type: Article

References (54)

1. 21 steroid side chain cleavage. Spectral and binding studies. J Biol Chem 256 (1981) 6134-6139
2. 17,20 lyase). J Biol Chem 256 (1981) 3871-3876
3. 17,20-lyase) associated with one protein. Biochemistry 20 (1981) 4037-4042
4. Zuber M.X., Simpson E.R., and Waterman M.R. Expression of bovine 17α-hydroxylase cytochrome P450 cDNA in nonsteroidogenic (COS 1) cells. Science 234 (1986) 1258-1261
5. 21scc: one enzyme with two actions: hydroxylase and lyase. J Steroid Biochem Mol Biol 40 (1991) 527-532
6. Denis L.J., and Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 18 (2000) 52-74
7. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253 (2003) 89-101
8. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
9. Huggins C., Stevens R.E., and Hodges C.V. Studies on prostatic cancer. II. The effect of castration on clinical patients with carcinoma of the prostate. Arch Surg 43 (1941) 209
10. Resnick M.I., and Grayhack J.T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2 (1975) 141-161 references cited therein
11. Koivisto P., Kolmer M., Visakorpi T., and Kallioniemi O.P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152 (1998) 1-9 references cited therein
12. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
13. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 1488-1490
14. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
15. Black R.J., Bray F., Ferlay J., and Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33 (1997) 1075-1107
16. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
17. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
18. 17,20-lyase). Endocr Relat Cancer 3 (1996) 25-39
19. 17α and 5α-steroid reductase. Nat Prod Rep 15 (1998) 495-512
20. Njar V.C., and Brodie A.M. Inhibitors of 17α-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr Pharm Des 5 (1999) 163-180
21. Hartmann R.W., Ehmer P.B., Haidar S., Hector M., Jose J., Klein C.D., et al. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Arch Pharm Pharm Med Chem 335 (2002) 119-128
22. Leroux F. Inhibition of P450 17 as a new strategy for the treatment of prostate cancer. Curr Med Chem 12 (2005) 1623-1629
23. Hakki T., and Bernhardt R. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther 111 (2006) 27-52
24. Pont A., Williams P.L., Azhar S., Reitz R.E., Bochra C., Smith E.R., et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 142 (1982) 2137-2140
25. Santen R.J., Van den Bossche H., Symoens J., Brugmans J., and De Coster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 57 (1983) 732-736
26. Trachtenberg J., and Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 2 (1984) 433-435
27. De Coster R., Caers I., Coene M.C., Amery W., Beerens D., and Haelterman C. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol 24 (1986) 657-664
28. Muscato J.J., Ahmann T.A., Johnson K.M., Wilding W., Monaghan G., and Schlossman D.M. Optimal dosing of ketoconazole (KETO) and hydrocortisone (HC) leads to long responses in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 13 (1994) 229
29. Lake-Bakaar G., Scheuer P.J., and Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ 294 (1987) 419-422
30. Nakabayashi M., Xie W., Regan M.M., Jackman D.M., Kantoff P.W., and Oh W.K. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107 (2006) 975-981
31. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J Urol 175 (2006) 27-34
32. 17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 38 (1995) 2463-2471
33. 17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
34. Attard G., Belldegrun A.S., and De Bono J.S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96 (2005) 1241-1246
35. Attard G., Reid A.H.M., Barrett M., Karavasilis V., Molife R., Thompson E., et al. Inhibition of androgen synthesis results in a high response rate in castration refractory prostate cancer. American association for cancer research annual meeting. Los Angeles, EUA (2007)
36. 16-steroids; inhibitors of 17α-hydroxylase/17,20-lyase (17α-lyase). Bioorg Med Chem Lett 6 (1996) 2777-2782
37. 17α): potential agents for the treatment of prostate cancer. J Med Chem 41 (1998) 902-912
38. Handratta V.D., Vasaitis T.S., Njar V.C., Gediya L.K., Kataria R., Chopra P., et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48 (2005) 2972-2984
39. Siddiqui A.U., Rao V.U.M., Maimirani M., and Siddiqui A.H. Heterocyclic steroids: synthesis of androsteno[17,16-d]pyrazoles and androsteno[17,16-e]pyrimidines. J Heterocycl Chem 32 (1995) 353-354
40. 17α (17α-hydroxylase-17,20-lyase). J Chem Soc Perkin Trans I (1994) 263-267
41. 17,20-lyase inhibitors. Anal Biochem 267 (1999) 319-330
42. 17α). J Med Chem 40 (1997) 3297-3304
43. Njar V.C., Klus G.T., Johnson H.H., and Brodie A.M. Synthesis of novel 21-trifluoropregnane steroids: inhibitors of 17α-hydroxylase/17,20-lyase (17α-lyase). Steroids 62 (1997) 468-473
44. 17,20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Cancer Res 58 (1998) 3826-3832
45. 17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer 81 (1999) 622-630
46. Nnane I.P., Kato K., Liu Y., Long B.J., Lu Q., Wang X., et al. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Endocrinology 140 (1999) 2891-2897
47. Nnane I.P., Njar V.C., Liu Y., Lu Q., and Brodie A.M. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J Steroid Biochem Mol Biol 71 (1999) 145-152
48. Nnane I.P., Long B.J., Ling Y.Z., Grigoryev D.N., and Brodie A.M. Anti-tumour effects and pharmacokinetic profile of 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br J Cancer 83 (2000) 74-82
49. 17α inhibitors: 17-(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstene derivatives. Steroids 68 (2003) 603-611
50. Wong C., Kelce W.R., Sar M., and Wilson E.M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270 (1995) 19998-20003
51. Yarbrough W.G., Quarmby V.E., Simental J.A., Joseph D.R., Sar M., Lubahn D.B., et al. A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat. J Biol Chem 265 (1990) 8893-8900
52. Meyer M.D., and Kruse L.I. Ergoline synthons: synthesis of 3,4-dihydro-6-methoxybenz[cd]indol-5(1H)-one (6-methoxy-Uhle's ketone) and 3,4-dihydrobenz[cd]indol-5(1H)-one (Uhle's ketone) via a novel decarboxylation of indole-2-carboxylates. J Org Chem 49 (1984) 3195-3199
53. 13C NMR parameters of azoles. Magn Reson Chem 26 (1988) 134-151
54. Long B.J., Grigoryev D.N., Nnane I.P., Liu Y., Ling Y.Z., and Brodie A.M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60 (2000) 6630-6640